A Phase 3 interventional study of ampicillin sodium/sulbactam sodium in Pneumonia, Bacterial, sponsored by Pfizer. Completed at 22 sites in Japan. Open to participants aged 16 Years to 79 Years. Per ClinicalTrials.gov, last updated 2012-07-13.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Unasyn-S 12g/day (3 g four times a day) is the commonly used dosage depending on the severity for US, EU, China, Taiwan and Korea for over 20 years, however, Unasyn-S 12g/day has not yet been approved in Japan. The purpose of this trial is to evaluate the clinical efficacy and safety in Japanese adult subjects with community acquired pneumonia receiving ampicillin sodium/sulbactam sodium, 12g/day (3 g four times a day ) IV.
153 studies on the registry are indexed under Pneumonia, Bacterial; 27 are open to participants now.
This study's enrollment of 47 is below the median of 132 across 107 interventional studies indexed under Pneumonia, Bacterial.
Browse Pneumonia, Bacterial studies →Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ampicillin sodium/sulbactam sodium 12g/day (3 g four times a day) IV
Drug: ampicillin sodium/sulbactam sodium
Drug pages: Ampicillin · Sulbactam
ampicillin sodium/sulbactam sodium is administered 12g/day (3 g four times a day) intravenously for 3 to 14 days
Also known as: Unasyn-S
Response Rate (Clinical Response, Data Review Committee Assessment)
Response rate was calculated from the following formula, "the number of participants assessed as effective" over "total participants excluding ones assessed as indeterminate" multiplied by 100.
Time frame: End of treatment, Test of cure (7 days after End of treatment), Long term follow up (7 days after Test of cure)
Response Rate (Clinical Response, Investigator Assessment)
Response rate was calculated from the following formula, "the number of participants assessed as effective" over "total participants EXCLUDING ones assessed as indeterminate" multiplied by 100.
Time frame: End of treatment, Test of cure (7 days after End of treatment), Long term follow up (7 days after Test of cure)
The Tendency Toward Clinical Improvement (Investigator Assessment)
The number of participants who showed tendency toward clinical improvement based on the assessment of temperature, white blood cell count, C-reactive protein, clinical symptoms on Day 4 and was determined to continue the treatment.
Time frame: Day 4
Eradication Rate (Bacteriological Response, Data Review Committee Assessment)
Eradication Rate was calculated from the following formula, "the number of participants assessed as eradication, presumed eradication or microbial substitution" over "total participants excluding ones assessed as indeterminate" multiplied by 100. Microbial substitution means the appearance of new pathogens other than the original pathogens in a specimen from the same location with signs and symptoms of infection after the original pathogens were eradicated by treatment.
Time frame: Day 4, End of treatment, Test of cure (7 days after End of treatment), Long term follow up (7 days after Test of cure)
Eradication Rate (Bacteriological Response, Investigator Assessment)
Eradication Rate was calculated from the following formula, "the number of participants assessed as eradication , presumed eradication or microbial substitution" over "total participants excluding ones assessed as indeterminate" multiplied by 100. Microbial substitution means the appearance of new pathogens other than the original pathogens in a specimen from the same location with signs and symptoms of infection after the original pathogens were eradicated by treatment.
Time frame: Day 4, End of treatment, Test of cure (7 days after End of treatment), Long term follow up (7 days after Test of cure)
| Milestone | Ampicillin Sodium/Sulbactam Sodium |
|---|---|
| Started | 47 |
| Completed | 44 |
| Not completed | 3 |
| Withdrew: Lack of efficacy | 2 |
| Withdrew: Adverse event | 1 |
Response rate was calculated from the following formula, "the number of participants assessed as effective" over "total participants excluding ones assessed as indeterminate" multiplied by 100.
| percentage of participants | Ampicillin Sodium/Sulbactam Sodium |
|---|---|
| End of treatment (n=39) | 97.4 (86.5 to 99.9) |
| Test of cure (n=37) | 94.6 (81.8 to 99.3) |
| Long term follow up (n=36) | 94.4 (81.3 to 99.3) |
Response rate was calculated from the following formula, "the number of participants assessed as effective" over "total participants EXCLUDING ones assessed as indeterminate" multiplied by 100.
| percentage of participants | Ampicillin Sodium/Sulbactam Sodium |
|---|---|
| End of treatment (n=40) | 100.0 (91.2 to 100.0) |
| Test of cure (n=38) | 100.0 (90.7 to 100.0) |
| Long term follow up (n=34) | 100.0 (89.7 to 100.0) |
The number of participants who showed tendency toward clinical improvement based on the assessment of temperature, white blood cell count, C-reactive protein, clinical symptoms on Day 4 and was determined to continue the treatment.
| percentage of participants | Ampicillin Sodium/Sulbactam Sodium |
|---|---|
| The Tendency Toward Clinical Improvement (Investigator Assessment) | 100.0 |
Eradication Rate was calculated from the following formula, "the number of participants assessed as eradication, presumed eradication or microbial substitution" over "total participants excluding ones assessed as indeterminate" multiplied by 100. Microbial substitution means the appearance of new pathogens other than the original pathogens in a specimen from the same location with signs and symptoms of infection after the original pathogens were eradicated by treatment.
| percentage of participants | Ampicillin Sodium/Sulbactam Sodium |
|---|---|
| Day 4 (n=24) | 100.0 (85.8 to 100.0) |
| End of treatment (n=25) | 96.0 (79.6 to 99.9) |
| Test of cure (n=24) | 91.7 (73.0 to 99.0) |
| Long term follow up (n=21) | 95.2 (76.2 to 99.9) |
Eradication Rate was calculated from the following formula, "the number of participants assessed as eradication , presumed eradication or microbial substitution" over "total participants excluding ones assessed as indeterminate" multiplied by 100. Microbial substitution means the appearance of new pathogens other than the original pathogens in a specimen from the same location with signs and symptoms of infection after the original pathogens were eradicated by treatment.
| percentageof participants | Ampicillin Sodium/Sulbactam Sodium |
|---|---|
| Day 4 (n=23) | 95.7 (78.1 to 99.9) |
| End of treatment (n=24) | 100.0 (85.8 to 100.0) |
| Test of cure (n=23) | 95.7 (78.1 to 99.9) |
| Long term follow up (n=19) | 100.0 (82.4 to 100.0) |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ampicillin Sodium/Sulbactam Sodium | — | 1/47 (2.1%) | 19/47 (40.4%) |
| Event | Ampicillin Sodium/Sulbactam Sodium |
|---|---|
| PneumoniaInfections and infestations | 1/47 |
| Event | Ampicillin Sodium/Sulbactam Sodium |
|---|---|
| Alanine aminotransferase increasedInvestigations | 7/47 |
| Aspartate aminotransferase increasedInvestigations | 6/47 |
| ConstipationGastrointestinal disorders | 5/47 |
| Blood alkaline phosphatase increasedInvestigations | 4/47 |
| DiarrhoeaGastrointestinal disorders | 3/47 |
| NasopharyngitisInfections and infestations | 3/47 |
| Gamma-glutamyltransferase increasedInvestigations | 3/47 |
| PyrexiaGeneral disorders | 2/47 |
| HeadacheNervous system disorders | 2/47 |
| EczemaSkin and subcutaneous tissue disorders | 2/47 |
| Age Continuous(years) | Ampicillin Sodium/Sulbactam Sodium |
|---|---|
| Mean | 62.3 ± 16.4 |
| Sex: Female, Male(Participants) | Ampicillin Sodium/Sulbactam Sodium |
|---|---|
| Female | 21 |
| Male | 26 |
The record gives a start of Oct 2010, a primary completion of Apr 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.
Results were first posted in May 2012, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ampicillin · Sulbactam